Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:PerkinElmer
|
| gptkbp:acquisitionYear |
2021
|
| gptkbp:focusesOn |
tuberculosis diagnostics
|
| gptkbp:foundedIn |
2002
|
| gptkbp:founder |
Dr. Peter Wrighton-Smith
|
| gptkbp:headquartersLocation |
gptkb:Abingdon,_Oxfordshire,_United_Kingdom
|
| https://www.w3.org/2000/01/rdf-schema#label |
Oxford Immunotec
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
T-SPOT.TB test
|
| gptkbp:numberOfEmployees |
approximately 400
|
| gptkbp:operatesIn |
global
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:specializesIn |
diagnostic tests for infectious diseases
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
OXFD
|
| gptkbp:bfsParent |
gptkb:Patrick_J._Balthrop
|
| gptkbp:bfsLayer |
7
|